News|Videos|November 17, 2026

Sequential NITs Rule Out Advanced Fibrosis in Primary Care

Fact checked by: Sydney Jennings

FIB-4 followed by VCTE or ELF ruled out advanced fibrosis in most people with type 2 diabetes or complicated obesity in modeled primary care data.

A sequential approach using the Fibrosis-4 index (FIB-4) followed by vibration-controlled transient elastography (VCTE) or the Enhanced Liver Fibrosis (ELF) test ruled out advanced fibrosis in most people with type 2 diabetes or medically complicated obesity in a modeled US primary care population, according to data presented by Zobair M. Younossi, MD, MPH, at The Liver Meeting 2026 in Denver, Colorado.

“This is not general population screening. This is basically risk stratification or case finding,” Younossi, chairman of the Global NASH/MASH Council and professor and chairman of Beatty Liver and Obesity Research at Inova Health System in Falls Church, Virginia, told Patient Care Online.

Why Does Primary Care Matter?

Most people with type 2 diabetes or complicated obesity are managed in primary care, and Younossi says liver assessment should become as routine as eye and kidney checks. The American Diabetes Association recommends FIB-4 screening for adults with type 2 diabetes or prediabetes, followed by VCTE or ELF when FIB-4 is 1.3 or higher.1 Its performance in primary care, where advanced fibrosis is less common than at referral centers, had not been quantified.2

How Did the Algorithm Perform?

Investigators applied test performance from a biopsy-confirmed registry of 17,978 participants to advanced fibrosis prevalence estimated from NHANES 2017-2020 data. The algorithm ruled out advanced fibrosis in 67% of people with type 2 diabetes and 78% with medically complicated obesity, with negative predictive values of 95% and 97%, respectively. Overall, 12% and 6% were classified as having MASH with F2-F3 fibrosis or advanced fibrosis without cirrhosis, making them eligible for pharmacotherapy, while 3% and 2% had probable cirrhosis.2

Younossi says eligible patients may receive resmetirom (Rezdiffra) or semaglutide (Wegovy), while those with cirrhosis need liver cancer and varices surveillance.

Watch the full interview to hear Younossi discuss follow-up intervals for low-risk patients, key treatment thresholds, and how liver stiffness can flag clinically significant portal hypertension.


References

  1. American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(suppl 1):S61-S88. doi:10.2337/dc26-S004
  2. Younossi Z, Paik J, de Avila L, et al. Sequential algorithms using FIB-4, followed by VCTE or ELF to detect advanced fibrosis: validation of risk stratification strategy in the United States (U.S.) primary care setting. Presented at: The Liver Meeting 2026; November 5-9, 2026; Denver, CO.

Related to this article